Resistance to infection and activation of the monocyto-macrophage system caused by Bacillus firmus and its fractions
Jazyk angličtina Země Spojené státy americké Médium print
Typ dokumentu časopisecké články
PubMed
7959430
DOI
10.1007/bf02906811
Knihovny.cz E-zdroje
- MeSH
- adjuvancia imunologická izolace a purifikace farmakologie MeSH
- aktivace makrofágů účinky léků MeSH
- Bacillus subtilis imunologie MeSH
- Bacillus imunologie MeSH
- bakteriální vakcíny izolace a purifikace farmakologie MeSH
- hepatomegalie etiologie MeSH
- jaterní mikrozomy účinky léků metabolismus MeSH
- lipidy izolace a purifikace farmakologie MeSH
- listeriové infekce prevence a kontrola MeSH
- makrofágy účinky léků imunologie MeSH
- monocyty účinky léků imunologie MeSH
- myši MeSH
- splenomegalie etiologie MeSH
- systém (enzymů) cytochromů P-450 metabolismus MeSH
- techniky in vitro MeSH
- zvířata MeSH
- Check Tag
- myši MeSH
- ženské pohlaví MeSH
- zvířata MeSH
- Publikační typ
- časopisecké články MeSH
- Názvy látek
- adjuvancia imunologická MeSH
- bakteriální vakcíny MeSH
- lipidy MeSH
- systém (enzymů) cytochromů P-450 MeSH
Crude lipids isolated from Bacillus firmus, but not from other bacilli, were previously found to induce significant resistance against Listeria monocytogenes infection in mice. In this study, formaldehyde- and heat-killed bacterins of eight Bacillus species and some cellular fractions of B. firmus were prepared and tested for further immunomodulatory activities. Crude lipids, their aqueous extract, LTA, Protodyne and Pex-residue preparations exhibited a strong anti-infection activity, whereas Pextract, P40 and all bacterins tested had no effect. Formaldehyde-killed bacterins, live bacteria and the P40 preparation of both B. firmus strains, as well as bacterins of both B. subtilis strains, induced pronounced splenomegaly in mice. Peptidoglycan and Pex-residue induced significant depression of cytochrome P-450 in mouse liver microsomes after application of 0.1 mg per mouse. Optimal conditions for obtaining a bacterial suspension exhibiting these immunomodulatory properties were elaborated.
Zobrazit více v PubMed
Cancer Immunol Immunother. 1986;22(1):24-30 PubMed
Folia Microbiol (Praha). 1992;37(6):455-60 PubMed
Chemioterapia. 1985 Aug;4(4):310-2 PubMed
Asian Pac J Allergy Immunol. 1984 Jun;2(1):144-53 PubMed
Immunology. 1979 Dec;38(4):809-17 PubMed
J Clin Microbiol. 1987 Mar;25(3):540-5 PubMed
Proc Natl Acad Sci U S A. 1988 Oct;85(20):7452-6 PubMed
Eksp Onkol. 1985;7(5):18-20 PubMed
J Biol Chem. 1964 Jul;239:2370-8 PubMed
Chemioterapia. 1985 Dec;4(6):467-70 PubMed
Can J Biochem. 1968 Aug;46(8):899-904 PubMed
J Infect Dis. 1981 Jul;144(1):1-9 PubMed
Eksp Onkol. 1984;6(3):45-7 PubMed
Ann Immunol (Paris). 1982 Jul-Aug;133D(1):3-13 PubMed
Proc Soc Exp Biol Med. 1968 Feb;127(2):556-9 PubMed
Immunology. 1982 Jul;46(3):481-6 PubMed
Immunol Lett. 1981 Apr;3(1):39-43 PubMed
Acta Pathol Microbiol Scand C. 1981 Dec;89(6):373-8 PubMed
Boll Ist Sieroter Milan. 1987;66(5):391-4 PubMed
Neoplasma. 1984;31(1):65-74 PubMed
Mikrobiol Zh. 1986 Jan-Feb;48(1):77-81 PubMed
Immunology. 1986 Aug;58(4):577-81 PubMed
Immunomodulatory properties of subcellular fractions of a G+ bacterium, Bacillus firmus
Immunomodulatory effects of Bacillus firmus on mouse peritoneal cells in vitro
Immunostimulatory effect of Bacillus firmus on mouse lymphocytes
Immunomodulatory effects of Bacillus firmus
Polyclonal activation of human lymphocytes by Bacillus firmus and its constituents
